Validation of novel fluorescence assays for the routine screening of drug susceptibilities of Trichomonas vaginalis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 933-943

  Natto, Manal J ^a   Savioli, Francesca ^a   Quashie, Neils B ^a,b   Dardonville, Christophe ^c   Rodenko, Boris ^d   de Koning, Harry P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GHANA   (Ghana)

^c INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Alamar blue; Drug screening; Propidium iodide; Resazurin; Resorufin; Trichomoniasis

Indexed keywords

ANTITRICHOMONAL AGENT; ASCORBIC ACID; FLUORESCENT DYE; METRONIDAZOLE; PHOSPHODIESTERASE INHIBITOR; PHOSPHONIUM DERIVATIVE; PROPIDIUM IODIDE; RESAZURIN; RESORUFIN;

ANAEROBIC GROWTH; ARTICLE; CELL DENSITY; DRUG SENSITIVITY; FLUORESCENCE ANALYSIS; MICROBIAL METABOLISM; MOLECULAR STABILITY; PARASITE EXAMINATION; REDUCTION KINETICS; REPRODUCIBILITY; TRICHOMONAS VAGINALIS;

ANTIPROTOZOAL AGENTS; FEMALE; FLUORESCENCE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; OXAZINES; PARASITIC SENSITIVITY TESTS; PROPIDIUM; STAINING AND LABELING; TRICHOMONAS VAGINALIS; XANTHENES;

EID: 84858649281     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr572     Document Type: Article

References (43)

1. Johnston VJ, Mabey DC. Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis 2008; 21: 56-64.
2. Grodstein F, Goldman MB, Cramer DW. Relation of tubal infertility to history of sexually transmitted diseases. Am J Epidemiol 1993; 137: 577-84.
3. Cotch MF, Pastorek JG 2nd, Nugent RP et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis 1997; 24: 353-60.
4. Soper D. Trichomoniasis: under control or undercontrolled? Am J Obstet Gynecol 2004; 190: 281-90.
5. Van Der Pol B, Kwok C, Pierre-Louis B et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 2008; 197: 548-54.
6. McClelland RS, Sangare L, Hassan WM et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195: 698-702.
7. Viikki M, Pukkala E, Nieminen P et al. Gynaecological infections as risk determinants of subsequent cervical neoplasia. Acta Oncol 2000; 39: 71-5.
8. Zhang ZF, Begg CB. Is Trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol 1994; 23: 682-90.
9. Swygard H, Seña AC, Hobbs MM et al. Trichomoniasis: clinical manifestations, diagnosis and management. Sex Transm Infect 2004; 80: 91-5.
10. Cudmore SL, Delgaty KL, Hayward-McClelland SF et al. Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev 2004; 17: 783-93.
11. Schmid G, Narcisi E, Mosure D et al. Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001; 46: 545-9.
12. Dunne RL, Dunn LA, Upcroft P et al. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003; 13: 239-49.
13. Wright JM, Dunn LA, Kazimierczuk Z et al. Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine. Parasitol Res 2010; 107: 847-53.
14. Giordani RB, De Almeida MV, Fernandes E et al. Anti-Trichomonas vaginalis activity of synthetic lipophilic diamine and amino alcohol derivatives. Biomed Pharmacother 2009; 63: 613-7.
15. Sears SD, O'Hare J. In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents. Antimicrob Agents Chemother 1988; 32: 144-6.
16. Al-Salabi MI, De Koning HP. Purine nucleobase transport in amastigotes of Leishmania mexicana: involvement in allopurinol uptake. Antimicrob Agents Chemother 2005; 49: 3682-9.
17. Räz B, Iten M, Grether-Bühler Y et al. The Alamar blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. gambiense) in vitro. Acta Trop 1997; 68: 139-47.
18. Wallace LJM, Candlish D, De Koning HP. Different substrate recognition motifs of human and trypanosome nucleobase transporters: selective uptake of purine antimetabolites. J Biol Chem 2002; 277: 26149-56.
19. Pfaller MA, Vu Q, Lancaster M et al. Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 1994; 32: 1625-8.
20. Slaughter MR, Bugelski PJ, O'Brien PJ. Evaluation of Alamar blue reduction for the in vitro assay of hepatocyte toxicity. Toxicol In Vitro 1999; 13: 567-9.
21. O'Brien J, Wilson I, Orton T et al. Investigation of the Alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267: 5421-6.
22. Rodenko B, Van der Burg AM, Wanner MJ et al. 2, N6-Disubstituted adenosine analogs with antitrypanosomal and antimalarial activities. Antimicrob Agents Chemother 2007; 51: 3796-802.
23. Campos Aldrete ME, Salgado-Zamora H, Luna J et al. A high-throughput colorimetric and fluorometric microassay for the evaluation of nitroimidazole derivatives anti-Trichomonas activity. Toxicol In Vitro 2005; 19: 1045-50.
24. Duarte M, Giordani RB, De Carli GA et al. A quantitative resazurin assay to determinate the viability of Trichomonas vaginalis and the cytotoxicity of organic solvents and surfactant agents. Exp Parasitol 2009; 123: 195-8.
25. Mokoka TA, Zimmermann S, Julianti T et al. In vitro screening of traditional South African malaria remedies against Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Leishmania donovani, and Plasmodium falciparum. Planta Med 2011; 77: 1663-7.
26. Gould MK, Vu XL, Seebeck T et al. Propidium iodide-based methods for monitoring drug action in the kinetoplastidae: comparison with the Alamar blue assay. Anal Biochem 2008; 382: 87-93.
27. Westrop GD, Goodall G, Mottram JC et al. Cysteine biosynthesis in Trichomonas vaginalis involves cysteine synthase utilizing O-phosphoserine. J Biol Chem 2006; 281: 25062-75.
28. Clackson TE, Coombs GH. The antagonistic effects of acetate and lactate upon the trichomonacidal activity of metronidazole. J Antimicrob Chemother 1983; 11: 401-6.
29. Hollander DH. Colonial morphology of Trichomonas vaginalis in agar. J Parasitol 1976; 62: 826-8.
30. Clark CG, Diamond LS. Methods for cultivation of luminal parasitic protists of clinical importance. Clin Microbiol Rev 2002; 15: 329-41.
31. Diamond LS. The establishment of various trichomonads of animals and man in axenic cultures. J Parasitol 1957; 43: 488-90.
32. Battaglia M, Pozzi D, Grimaldi S et al. Hoechst 33258 staining for detecting mycoplasma contamination in cell cultures: a method for reducing fluorescence photobleaching. Biotech Histochem 1994; 69: 152-6.
33. Luque-Ortega JR, Reuther P, Rivas L et al. New benzophenone-derived bisphosphonium salts as leishmanicidal leads targeting mitochondria through inhibition of respiratory complex II. J Med Chem 2010; 53: 1788-98.
34. De Koning HP, Gould MK, Sterk GJ et al. Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets. J Infect Dis 2012; in press.
35. Sobel JD, Nagappan V, Nyirjesy P. Metronidazole-resistant vaginal trichomoniasis-an emerging problem. N Engl J Med 1999; 341: 292-3.
36. Cudmore SL, Garber GE. Prevention or treatment: the benefits of Trichomonas vaginalis vaccine. J Infect Pub Health 2010; 3: 47-53.
37. Willcox RR. Epidemiological aspects of human trichomoniasis. Br J Vener Dis 1960; 36: 167-74.
38. Hollander DH, Frost JL. Demonstration of a minimum oxidation-reduction potential requirement for Trichomonas vaginalis. J Bacteriol 1965; 89: 1610-2.
39. Maeda H, Matsu-ura S, Yamauchi Y et al. Resazurin as an electron acceptor in glucose oxidase-catalyzed oxidation of glucose. Chem Pharm Bull 2001; 49: 622-5.
40. Hrdý I, Hirt RP, Dolezal P et al. Trichomonas hydrogenosomes contain the NADH dehydrogenase module of mitochondrial complex I. Nature 2004; 432: 618-22.
41. Hrdý I, Cammack R, Stopka P et al. Alternative pathway of metronidazole activation in Trichomonas vaginalis hydrogenosomes. Antimicrob Agents Chemother 2005; 49: 5033-6.
42. Leitsch D, Kolarich D, Binder M et al. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol Microbiol 2009; 72: 518-36.
43. Talbot JD, Barrett JN, Barrett EF et al. Rapid, stimulation-induced reduction of C12-resorufin in motor nerve terminals: linkage to mitochondrial metabolism. J Neurochem 2008; 105: 807-19.